Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Hemay 020 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Tianjin Hemay Biotech
- 25 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 27 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.